Loading clinical trials...
Loading clinical trials...
Tamoxifen in Duchenne Muscular Dystrophy: A Multicenter, Randomised, Double-blind, Placebo-controlled, Phase 3 Safety and Efficacy 48-week Trial
Conditions
Interventions
Tamoxifen
Matching placebo
Locations
11
France
Hôpitaux Raymond Poincaré
Garches, France
Hôpital de Hautepierre
Strasbourg, France
DRK Klinik Berlin Westend
Berlin, Germany
Universitätsklinikum Essen
Essen, Germany
Radboud umc
Nijmegen, Netherlands
Hospital Sant Joan de Déu. UB
Esplugues de Llobregat, Barcelona, Spain
Start Date
June 12, 2018
Primary Completion Date
July 25, 2022
Completion Date
October 18, 2022
Last Updated
December 20, 2022
NCT07037862
NCT07160634
NCT06450639
NCT07129954
NCT06290713
NCT06925269
Lead Sponsor
University Hospital, Basel, Switzerland
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions